TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06539507: A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

Sponsor: BioCryst Pharmaceuticals · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 78 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,149,540

Rescue Site Savings

+$750,720

Unlock Full NCT06539507 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06539507 Rescue Dossier →